Press Releases

July 12, 2022
jCyte Announces Appointment of Dr. Stewart Craig as Chief Technology Officer

November 15, 2021
jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapy

November 2, 2021
jCyte Announces Appointment of Peter C. Kuper as Senior Vice President of Finance and Information Technology

October 19, 2021
jCyte Announces Appointment of John Pollack, MD, FASRS, as Chief Medical Officer

September 21, 2021
jCyte Announces Appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations

September 9, 2021
jCyte Announces Appointment of Victor Chao as Vice President of CMC Operations

July 6, 2021
jCyte Announces Appointment of Adrian Morris as Chief Development Officer

June 22, 2021
jCyte Announces Appointment of Dr. Adam Walsh as Chief Financial Officer

May 25, 2021
jCyte Announces Appointment of John Sholar as General Counsel  

May 3, 2021
jCyte, Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy  

April 22, 2021
jCyte Inc. Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

February 21, 2021
jCyte Announces Promotion of Dr. Shannon Blalock to Chief Executive Officer

June 30,2020
jCyte Inc. Announces Scientific Advisory Board with Distinguished Retinal Physicians

May 8, 2020
jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical

In the News

BioSpace | May 1, 2021
jCyte Announces Promising Phase IIb Results for Allogeneic Retinal Stem Cell Therapy

Opthalmology Times | Oct 5, 2020
Intravitreally injected hRPCs improve vision in retinitis pigmentosa cases

Financial Times | Sept 14, 2020
Cell therapy opens up new cure horizons

Retinal Physician | Sept 1, 2020
Trial data on gene therapy, proposed Medicare cuts, FDA clearance of an AI diagnostic for DR, and more.

Optical Journal | Aug 13, 2020
jCyte Inc. Announces Promising Results In Retinitis Pigmentosa

The Stem Cellar  | July 29, 2020
Encouraging news for treatment targeting retinitis pigmentosa

Eyewire News | July 27, 2020
jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosa

Endpoints News | July 27, 2020
Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb

Review of Ophthalmology | July 9, 2020
Regenerative Medicine In Ophthalmology

UCI | June 4, 2020
UCI Startup Company jCyte Partners with Santen Pharmaceutical

Orange County Business Journal | May 27, 2020
Biotech jCyte Inks $252M Licensing Deal

Healio | May 14, 2020
Santen to commercialize jCyte’s jCell therapy outside US

The Stem Cellar | May 11, 2020
A Clear Vision for the Future

Global Genes | May 11, 2020
JCyte Licenses Ex-US Rights to Retinitis Pigmentosa Cell Therapy to Santen for $252 Million

Pharmaceutical Business Review | May 11, 2020
JCyte signs ex-US licensing deal with Santen for retinal disease therapy

The Pharma Letter | May 9, 2020
jCyte out-licenses rare vision disorder treatment for $252 million

Biocentury | May 8, 2020
jCyte-Santen deal positions CIRM-funded stem cell therapy for pivotal studies, global access

Bioworld | May 8, 2020
Santen inks $252M license to Jcyte ocular cell therapy

Media Contact

 

Robert Beathard
Sr. Vice President, Corporate Development
media@jcyte.com